{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:31:41Z","timestamp":1793291501993,"version":"4.5.0"},"reference-count":41,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals younger than 18 years with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to either no treatment or conventional therapy (phosphate and active vitamin D) or evaluating conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We screened 4114 records and assessed 254 full texts. One RCT and one post hoc study proved eligible when comparing burosumab to conventional therapy or no treatment. The open-label RCT was at high RoB, with certainty of evidence ranging from moderate to very low. Burosumab, compared to conventional therapy, probably prevents lower limb deformity and improves physical health quality of life (QoL) (moderate certainty). Burosumab may increase height and enhance the burden of symptoms related to chronic hypophosphatemia (low certainty). Burosumab probably increases treatment-emergent adverse events (moderate certainty) and may increase dental abscesses (low certainty). One observational study assessing conventional therapy vs no treatment was at high RoB, providing very low certainty evidence regarding the impact of conventional therapy on final height.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our review indicates that burosumab likely provides benefits to children by preventing lower limb deformity and improving physical health QoL while potentially increasing height. However, burosumab may also increase adverse events. Our review found limited evidence regarding the impact of conventional therapy compared to no treatment on final height. Further research is required to understand the long-term effect of medical therapy in children.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf011","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:25:27Z","timestamp":1736454327000},"page":"1205-1217","source":"Crossref","is-referenced-by-count":11,"title":["Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-5548","authenticated-orcid":false,"given":"Dalal S","family":"Ali","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON, Canada L8S 4L8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-4208","authenticated-orcid":false,"given":"Reza D","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada L8S 4L8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-4822","authenticated-orcid":false,"given":"Salma","family":"Hussein","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON, Canada L8S 4L8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-9702","authenticated-orcid":false,"given":"Farah","family":"Alsarraf","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON, Canada L8S 4L8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-7894","authenticated-orcid":false,"given":"R Todd","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine & Dentistry, The University of Alberta , Edmonton, AB, Canada T6G 2R3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-3237","authenticated-orcid":false,"given":"Hajar","family":"Abu Alrob","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada L8S 4L8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha M","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center , 2300 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3970","authenticated-orcid":false,"given":"Martin","family":"Biosse-Duplan","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Universit\u00e9 Paris Cit\u00e9 , 75006 Paris ,","place":["France"]},{"name":"Institut Imagine, INSERM 1163 , 75015 Paris ,","place":["France"]},{"name":"Department of Odontology, Bretonneau Hospital, APHP , 75006 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS, 20132 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-6768","authenticated-orcid":false,"given":"Thomas O","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (Endocrinology), and Orthopedics and Rehabilitation, Yale University School of Medicine , New Haven, CT 06520 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3936","authenticated-orcid":false,"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Universit\u00e9 Paris Cit\u00e9 , 75006 Paris ,","place":["France"]},{"name":"Institut Imagine, INSERM 1163 , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-8419","authenticated-orcid":false,"given":"Karel","family":"Dandurand","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Universit\u00e9 de Sherbrooke , Sherbrooke, QC, Canada J1H 5N4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1891-6765","authenticated-orcid":false,"given":"Guido","family":"Filler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Endocrinology Division, Western University , London, ON, Canada N6A 3K7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine Pontificia Universidad Cat\u00f3lica de Chile , 8320165 Santiago, Regi\u00f3n Metropolitana, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-3469","authenticated-orcid":false,"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tamaki-Aozora Hospital , 779-3125 Tokushima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-4603","authenticated-orcid":false,"given":"Corinna","family":"Grasemann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Rare Diseases, Katholisches Klinikum Bochum and Ruhr-University Bochum , 44791 Bochum ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-3467","authenticated-orcid":false,"given":"Erik A","family":"Imel","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pediatrics, Endocrinology, Indiana University School of Medicine , Indianapolis, IN 46202 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7732","authenticated-orcid":false,"given":"Suzanne M","family":"Jan de Beur","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia School of Medicine , Charlottesville, VA 22903 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9271-0379","authenticated-orcid":false,"given":"Emmett","family":"Morgante","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, University of Waterloo , Waterloo, ON, Canada N2L 3G1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M","family":"Ward","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa , Ottawa, ON, Canada K1H 8L1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8956","authenticated-orcid":false,"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON, Canada L8S 4L8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5718","authenticated-orcid":false,"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada L8S 4L8"},{"name":"Department of Medicine, McMaster University , Hamilton, ON, Canada L8S 4L8"},{"name":"MAGIC Evidence Ecosystem Foundation [www.magicevidence.org] , Oslo 0456 ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"5","key":"2025042208270799700_dgaf011-B1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2025042208270799700_dgaf011-B2","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025042208270799700_dgaf011-B3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025042208270799700_dgaf011-B4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0022034516677528","article-title":"Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia","volume":"96","author":"Biosse Duplan","year":"2017","journal-title":"J Dent Res"},{"key":"2025042208270799700_dgaf011-B5","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7650","key":"2025042208270799700_dgaf011-B6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2025042208270799700_dgaf011-B7","doi-asserted-by":"publisher","author":"Ali","DOI":"10.13140\/RG.2.2.24562.21446"},{"key":"2025042208270799700_dgaf011-B8","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025042208270799700_dgaf011-B9","author":"Busse"},{"key":"2025042208270799700_dgaf011-B10","author":"Wells"},{"key":"2025042208270799700_dgaf011-B11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","article-title":"GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence","volume":"87","author":"Guyatt","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2025042208270799700_dgaf011-B12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2015.12.007","article-title":"Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format","volume":"74","author":"Carrasco-Labra","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2025042208270799700_dgaf011-B13","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"8","key":"2025042208270799700_dgaf011-B14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3899\/jrheum.200990","article-title":"Meaningful change thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis","volume":"48","author":"Beaumont","year":"2021","journal-title":"J Rheumatol"},{"issue":"1","key":"2025042208270799700_dgaf011-B15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-017-0633-1","article-title":"Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome","volume":"12","author":"Schrover","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025042208270799700_dgaf011-B16","author":"Saris-Baglama"},{"issue":"10189","key":"2025042208270799700_dgaf011-B17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"The Lancet"},{"issue":"5","key":"2025042208270799700_dgaf011-B18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","article-title":"Patient-Reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia","volume":"108","author":"Padidela","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2025042208270799700_dgaf011-B19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40618-022-01768-9","article-title":"Growth in height and body proportion from birth to adulthood in hereditary hypophosphatemic rickets: a retrospective cohort study","volume":"45","author":"Del Pino","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2025042208270799700_dgaf011-B20","doi-asserted-by":"crossref","first-page":"e10672","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"issue":"11","key":"2025042208270799700_dgaf011-B21","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","article-title":"Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level","volume":"108","author":"Imel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025042208270799700_dgaf011-B22","doi-asserted-by":"crossref","first-page":"1111104","DOI":"10.3389\/fendo.2023.1111104","article-title":"The ankle in XLH: reduced motion, power and quality of life","volume":"14","author":"Akta","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2025042208270799700_dgaf011-B23","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025042208270799700_dgaf011-B24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2025042208270799700_dgaf011-B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33393\/ao.2023.2513","article-title":"X-linked hypophosphatemic rickets: cases series and literature review with a focus on neurosurgical management","volume":"10","author":"Baronio","year":"2023","journal-title":"AboutOpen"},{"key":"2025042208270799700_dgaf011-B26","doi-asserted-by":"crossref","first-page":"116763","DOI":"10.1016\/j.bone.2023.116763","article-title":"X-linked hypophosphatemia in 4 generations due to an exon 13-15 duplication in PHEX, in the absence of the c.*231A &gt; G variant","volume":"172","author":"Soto Barros","year":"2023","journal-title":"Bone"},{"issue":"1","key":"2025042208270799700_dgaf011-B27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4274\/jcp.2022.83435","article-title":"A novel PHEX mutation in A case followed up with A diagnosis of X-linked hypophosphatemic rickets","volume":"21","author":"Demirba\u015f","year":"2023","journal-title":"Gu\u0308ncel pediatri"},{"issue":"10","key":"2025042208270799700_dgaf011-B28","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"2025042208270799700_dgaf011-B29","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"2025042208270799700_dgaf011-B30","doi-asserted-by":"crossref","first-page":"E954","DOI":"10.1210\/jc.2012-4133","article-title":"Cortical and trabecular bone density in X-linked hypophosphatemic rickets","volume":"98","author":"Cheung","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025042208270799700_dgaf011-B31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/BPO.0000000000002393","article-title":"Predicting rates of angular correction after hemiepiphysiodesis in patients with X-linked hypophosphatemic rickets","volume":"43","author":"Grote","year":"2023","journal-title":"J Pediatr Orthop"},{"issue":"2","key":"2025042208270799700_dgaf011-B32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00860736","article-title":"Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease","volume":"9","author":"Taylor","year":"1995","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"2025042208270799700_dgaf011-B33","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"8","key":"2025042208270799700_dgaf011-B34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"21","key":"2025042208270799700_dgaf011-B35","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2025042208270799700_dgaf011-B36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/clinem\/dgad440","article-title":"Efficacy and safety of burosumab in X-linked hypophosphataemia: systematic review and meta-analysis","volume":"109","author":"Wang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025042208270799700_dgaf011-B37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025042208270799700_dgaf011-B38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2025042208270799700_dgaf011-B39","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025042208270799700_dgaf011-B40","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","article-title":"Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets","volume":"37","author":"Paloian","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"2025042208270799700_dgaf011-B41","doi-asserted-by":"crossref","first-page":"1414509","DOI":"10.3389\/fendo.2024.1414509","article-title":"Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf011\/61398153\/dgaf011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/5\/1205\/61398153\/dgaf011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/5\/1205\/61398153\/dgaf011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:27:23Z","timestamp":1745324843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/5\/1205\/7950789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf011","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,9]]}}}